# Tocilizumab

## Actemra inj 162mg/0.9mL

##### 臨採

| TAH Drug Code      | [IACTM](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IACTM)                                                                                                                                                                                                                                                                                                          |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Moderate to severe active RA in adult patients, given alone or in combination w/ methotrexate (MTX) &/or other DMARDs.                                                                                                                                                                                                                                                          |
| Dosing             | SC, rheumatoid arthritis, giant cell arteritis: <100 kg 162 mg once every other week, increase to 162 mg once a week based on clinical response; > or =100 kg 162 mg once a week.                                                                                                                                                                                               |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                   |
| Contraindications  | Hypersensitivity to tocilizumab.                                                                                                                                                                                                                                                                                                                                                |
| Adverse Effects    | Upper resp tract infections, cellulitis, oral herpes simplex, herpes zoster; abdominal pain, mouth ulceration, gastritis; rash, pruritus, urticaria; headache, dizziness; increased hepatic transaminases, increased wt; HTN; leucopenia, neutropenia; hypercholesterolaemia; peripheral oedema, hypersensitivity reaction, inj site reaction; cough, dyspnoea; conjunctivitis. |
| Pregnancy          | No (Limited) Human Data – Probably Compatible                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                   |
| More Info          | [UpToDate](https://www.uptodate.com/contents/tocilizumab-drug-information)                                                                                                                                                                                                                                                                                                      |

## Actemra Infusion 80mg/4mL/Vial (限Covid-19)

##### 臨採

| TAH Drug Code      | [IACTMV](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IACTMV)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | - Rheumatoid Arthritis (RA): For adults with moderate to severe RA who have not responded to or cannot tolerate DMARDs or TNF antagonists. Can be used alone if MTX is unsuitable. - RA, MTX-naive: For adults with severe, active, progressive RA who have not                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Dosing             | - COVID-19: Recommended dose for hospitalized adults: 8 mg/kg via a single 60-minute IV infusion, not exceeding 800 mg. May give an additional dose at least 8 hours after the first if symptoms worsen or don’t improve. Subcutaneous administration is not ap                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Actemra is contraindicated in patients with a known hypersensitivity to tocilizumab or to any of the excipients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Adverse Effects    | Common: Hypertension (Adult, 4-7%), Injection site disorder (Rheumatoid arthritis, 2.4-10.1% ; polyarticular juvenile idiopathic arthritis, 28.8% ; systemic juvenile idiopathic arthritis, 41.2%), Rash (Rheumatoid arthritis, 2-4%), Constipation (COVID-19, 6-13%), Diarrhea (Adults, COVID-19, 4-6% ; Pediatric, >5%), Nausea (COVID-19, 3-4%), Upper abdominal pain (Adult, 2-3%), ALT/SGPT level raised (COVID-19, 3% ; rheumatoid arthritis, 0.7-48%; polyarticular or systemic juvenile idiopathic arthritis, 4-13%), Aspartate aminotransferase serum level above reference range (Rheumatoid arthritis, 0.1-41%; polyarticular or systemic juvenile idiopathic arthritis, <1-5%), Dizziness (Adult, 2-3%), Headache (Adults, 3-7%; pediatric, >5%), Insomnia (COVID-19, 4-5%), Anxiety (COVID-19, 3-6%), Nasopharyngitis (Rheumatoid arthritis, 4-7%; systemic juvenile idiopathic arthritis, 5% or higher), Infusion reaction (Rheumatoid arthritis, 7-8%; polyarticular juvenile idiopathic arthritis, 16-20.2%). Serious: Septic shock (COVID-19, 6%), Gastrointestinal perforation, Pancreatitis, Neutropenia (Rheumatoid arthritis, 1.8-3.7% ; polyarticular or systemic juvenile idiopathic arthritis, 7-15.4%), Thrombocytopenia (Up to 4%), Hepatotoxicity, Anaphylaxis, Hypersensitivity reaction (Up to 0.9%), Opportunistic infection, Tuberculosis, Upper respiratory infection (Rheumatoid arthritis, 6-8%; systemic juvenile idiopathic arthritis, 5% or higher), Cancer, Sepsis, Severe infectious disease. |
| Pregnancy          | No (Limited) Human Data – Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| More Info          | [UpToDate](https://www.uptodate.com/contents/tocilizumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

## Actemra Infusion 200mg/10mL/Vial(限Covid-19)

##### 臨採

| TAH Drug Code      | [IACTMV10](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IACTMV10)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | - Rheumatoid Arthritis (RA): For adults with moderate to severe RA who have not responded to or cannot tolerate DMARDs or TNF antagonists. Can be used alone if MTX is unsuitable. - RA, MTX-naive: For adults with severe, active, progressive RA who have not                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Dosing             | - COVID-19: Recommended dose for hospitalized adults: 8 mg/kg via a single 60-minute IV infusion, not exceeding 800 mg. May give an additional dose at least 8 hours after the first if symptoms worsen or don’t improve. Subcutaneous administration is not ap                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Actemra is contraindicated in patients with a known hypersensitivity to tocilizumab or to any of the excipients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Adverse Effects    | Common: Hypertension (Adult, 4-7%), Injection site disorder (Rheumatoid arthritis, 2.4-10.1% ; polyarticular juvenile idiopathic arthritis, 28.8% ; systemic juvenile idiopathic arthritis, 41.2%), Rash (Rheumatoid arthritis, 2-4%), Constipation (COVID-19, 6-13%), Diarrhea (Adults, COVID-19, 4-6% ; Pediatric, >5%), Nausea (COVID-19, 3-4%), Upper abdominal pain (Adult, 2-3%), ALT/SGPT level raised (COVID-19, 3% ; rheumatoid arthritis, 0.7-48%; polyarticular or systemic juvenile idiopathic arthritis, 4-13%), Aspartate aminotransferase serum level above reference range (Rheumatoid arthritis, 0.1-41%; polyarticular or systemic juvenile idiopathic arthritis, <1-5%), Dizziness (Adult, 2-3%), Headache (Adults, 3-7%; pediatric, >5%), Insomnia (COVID-19, 4-5%), Anxiety (COVID-19, 3-6%), Nasopharyngitis (Rheumatoid arthritis, 4-7%; systemic juvenile idiopathic arthritis, 5% or higher), Infusion reaction (Rheumatoid arthritis, 7-8%; polyarticular juvenile idiopathic arthritis, 16-20.2%). Serious: Septic shock (COVID-19, 6%), Gastrointestinal perforation, Pancreatitis, Neutropenia (Rheumatoid arthritis, 1.8-3.7% ; polyarticular or systemic juvenile idiopathic arthritis, 7-15.4%), Thrombocytopenia (Up to 4%), Hepatotoxicity, Anaphylaxis, Hypersensitivity reaction (Up to 0.9%), Opportunistic infection, Tuberculosis, Upper respiratory infection (Rheumatoid arthritis, 6-8%; systemic juvenile idiopathic arthritis, 5% or higher), Cancer, Sepsis, Severe infectious disease. |
| Pregnancy          | No (Limited) Human Data – Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| More Info          | [UpToDate](https://www.uptodate.com/contents/tocilizumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

